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Abstract
Tacrolimus (FK506) is an immunosuppressive drug that binds to the immunophilin FKBPB12. The FK506-FKBP12 complex
associates with calcineurin and inhibits its phosphatase activity, resulting in inhibition of nuclear translocation of nuclear
factor of activated T-cells (NFAT). There is increasing data supporting a critical role of NFAT in mediating angiogenic
responses stimulated by both vascular endothelial growth factor (VEGF) and a novel angiogenesis factor, secreted frizzled-
related protein 2 (SFRP2). Since both VEGF and SFRP2 are expressed in breast carcinomas, we hypothesized that tacrolimus
would inhibit breast carcinoma growth. Using IHC (IHC) with antibodies to FKBP12 on breast carcinomas we found that
FKBP12 localizes to breast tumor vasculature. Treatment of MMTV-neu transgenic mice with tacrolimus (3 mg/kg i.p. daily)
(n=19) resulted in a 73% reduction in the growth rate for tacrolimus treated mice compared to control (n=15), p=0.003;
which was associated with an 82% reduction in tumor microvascular density (p,0.001) by IHC. Tacrolimus (1 mM) inhibited
SFRP2 induced endothelial tube formation by 71% (p=0.005) and inhibited VEGF induced endothelial tube formation by
67% (p=0.004). To show that NFATc3 is required for SFRP2 stimulated angiogenesis, NFATc3 was silenced with shRNA in
endothelial cells. Sham transfected cells responded to SFRP2 stimulation in a tube formation assay with an increase in the
number of branch points (p,0.003), however, cells transfected with shRNA to NFATc3 showed no increase in tube
formation in response to SFRP2. This demonstrates that NFATc3 is required for SFRP2 induced tube formation, and
tacrolimus inhibits angiogenesis in vitro and breast carcinoma growth in vivo. This provides a rationale for examining the
therapeutic potential of tacrolimus at inhibiting breast carcinoma growth in humans.
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Introduction
Tumor angiogenesis is regulated by multiple proangiogenic
factors, of which the most widely studied is vascular endothelial
growth factor (VEGF). One of the pathways through which VEGF
stimulates angiogenesis is through activation of calcineurin/
nuclear factor of activated T-cells (NFAT) signaling [1–3]. Recent
work has identified a novel angiogenesis factor, secreted frizzled-
related protein 2 (SFRP2), which is expressed in the vasculature of
a wide variety of tumors including human breast carcinoma [4,5].
SFRP2 stimulates angiogenesis in the mouse Matrigel plug assay,
induces endothelial cell migration and tube formation in vitro, and
protects against hypoxia-induced apoptosis in endothelial cells [5].
SFRP2 belongs to a large family of secreted frizzle-related
proteins (SFRPs) which are related to the Wnt signaling cascade.
Wnt proteins have been grouped into two classes – canonical and
noncanonical – on the basis of their activity in cell lines or in vivo
assays. The core of the canonical Wnt pathway is the stability of
beta catenin [6]. SFRPs have been regarded as inhibitors of the
canonical Wnt-beta catenin pathway [6], while recent studies have
shown that SFRP2 can increase nuclear beta catenin levels [7–10].
In contrast we previously found that treatment of endothelial cells
with SFRP2 (at angiogenic doses) resulted in no change in nuclear
beta catenin levels in endothelial cells [5], suggesting that SFRP2
does not stimulate angiogenesis through inhibition or activation of
the Wnt/beta catenin pathway.
Noncanonical Wnts activate other signaling pathways, such as
the Wnt/Ca
2+ pathway [11]. The Wnt/Ca
2+ pathway is a beta
catenin-independent pathway for which signaling is mediated
through transient increases in cytoplasmic free calcium which
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dephosphorylates NFAT, which then translocates to from the
cytoplasm to the nucleus [12]. NFAT is a multigene family
containing five members: NFAT (NFATc1-c5). Except for
NFAT5, which is activated in response to osmotic stress [13], all
NFAT family members are regulated by the calcium-activated
protein phosphatase calcineurin and exist as transcriptionally
inactive, cytosolic phosphoproteins [12]. There is increasing data
supporting a critical role of NFAT in mediating angiogenic
responses [1–3]. Importantly, NFAT activation was identified as a
critical component of VEGF-induced angiogenesis and linked to
the induction of cyclooxygenase-2 [14], which is also a critical
player in angiogenesis. Our data suggested that NFAT may also
mediate SFRP2 induced angiogenesis, as treatment of endothelial
cells with SFRP2 resulted in an increase in nuclear NFATc3 [5].
In this study we further elucidate the role of both beta catenin
and NFATc3 in SFRP2 mediated angiogenesis through RNA
silencing, which confirms that NFATc3 is required for SFRP2
induced angiogenesis, while beta catenin is not. Thus, targeting
NFAT with a calcineurin inhibitor may be a therapeutic strategy
to inhibit both VEGF and SFRP2 induced angiogenesis.
Tacrolimus (FK506) is an immunosuppressive drug that binds to
the immunophlin FKBPB12, and the FK506-FKBP12 complex
associates with calcineurin and inhibits its phosphatase activity,
resulting in inhibition of nuclear translocation of NFAT [1].
Tacrolimus is FDA approved for the prevention of organ
transplant rejection and acts by inhibiting NFAT in lymphocytes
[15]. Since FKBP12 has been reported to be expressed in benign
and malignant vascular endothelium [16], we hypothesize that
FKBP12 is expressed in breast tumor endothelium, allowing
tacrolimus to inhibit breast tumor angiogenesis and tumor growth.
Materials and Methods
Treatment of MMTV-neu transgenic mice with tacrolimus
in vivo
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of North Carolina at Chapel Hill,
IACUC ID# 09-134.0. We had previously shown that treatment
with tacrolimus 3 mg/kg/day intraperitoneal (i.p.) was effective at
suppressing the growth of SVR angiosarcoma tumor in nude mice
as compared with control by 46% without signs of toxicity [5].
Using an FDA Oncology Calculator, we calculated this dose to be
equivalent to the human dose of 0.24 mg/kg/day [5], which is the
dose that is used to prevent human liver transplant rejection. To
evaluate whether tacrolimus would inhibit the growth rate of
breast tumors in vivo, we studied the efficacy of tacrolimus on the
growth of MMTV-neu tumors in transgenic mice. Female FVB/
N-Tg(MMTVneu) 202Mul/J mice were purchased from the
Jackson Laboratory (Bar Harbor, ME, Stock Number 002376).
The experimental female mice were bred in order to speed the
onset of tumorigenesis and were housed and inspected for tumor
development twice weekly. All animal work was conducted in
UNC DLAM animal facilities under an approved IACUC
protocol. Once tumors were detected by palpation or visual
inspection, tumor volume was documented using calipers and
tumor volume was calculated using the following formula: (shortest
diameter)
26(longest diameter)60.52. When tumors reached 100–
300 mm
3, mice were treated with either tacrolimus 3 mg/kg/day
i.p. in 20% Intralipid (Baxter, Deerfield, IL) or control (which
consisted of no treatment n=9 or 20% Intralipid i.p. n=6). All
tumors that were present from day 1 were measured. Mice used in
this study developed either one or two mammary tumors. Tumor
growth (assessed as percent change in tumor volume over initial
tumor volume) was calculated using the formula: [(final volu-
me2initial volume)/initial volume6100].
Antibodies
The following antibodies were purchased from Santa Cruz
Biotechnology, Inc., Santa Cruz, CA: FKBP12 (sc-28814),
NFTAc3 (sc- 8405), SFRP2 (sc-13940), and b-catenin (sc-59893).
The loading control, TATA binding protein TBP antibody
(ab818), was purchased from Abcam, Inc. (Cambridge, MA).
CD31 primary antibody was purchased from NeoMarkers
(Fremont, CA). Secondary antibodies were purchased from GE
Healthcare Bio-Sciences Corp. (Piscataway, NJ): ECL anti-mouse
IgG, HRP-linked whole antibody (NA931) and ECL anti-rabbit
IgG, HRP-linked whole antibody (NA934).
Immunohistochemistry
CD31 staining in mouse breast tumors. To show whether
the reduced growth rate of tacrolimus treated tumors correlates
with a decrease in tumor angiogenesis, we sectioned 4 control
tumors from mice treated with 20% intralipid and 4 tumors from
mice treated with tacrolimus. Breast tumors were sectioned at
5 mM onto Superfrost plus slides. Slides were dewaxed by
immersing in xylene three times for 5 minutes each. Slides were
hydrated in 100% ETOH, 95% ETOH, 70% ETOH, and 50%
ETOH for 3 minutes each. Slides were quenched in 3% H2O2
(DakoCytomation, LSAB2 HRP Kit, Carpinteria, CA) for
10 minutes, and then PBS for 3 minutes. Citra buffer
(BioGenex, San Ramon, CA) was warmed in a 60uC oven and
slides were immersed in citra buffer at 100uC in a rice steamer for
30 minutes. Slides were rinsed in PBS for 3 minutes and then
marked with a PAP pen. Goat serum (Pierce Biotechnology,
Rockford, IL) block (3 mg/ml) was applied for 10 minutes at room
temperature. Slides were rinsed twice in PBS for 3 minutes then
CD31 primary antibody (250 ml at 1:100 dilution) was applied and
slides were placed in a covered box in a 4uC cold room overnight.
Slides were then rinsed in PBS for 3 minutes, and 1–2 drops of
biotinylated secondary antibody (Ultravision Detection System,
LabVision Corp, Fremont, CA) was added to each slide for
20 minutes. Slides were rinsed twice in PBS for 3 minutes and 1–2
drops of streptavidin-HRP (Ultravision Detection System,
LabVision Corp, Fremont, CA) was applied for 20 minutes.
One-two drops of DAB complex (Ultravision Detection System,
LabVision Corp, Fremont, CA) was applied to each slide for
approximately 10 minutes. Slides were rinsed twice in distilled
water for 3 minutes each and counterstained with trypan blue
(Sigma, St Louis, MO) for 5 minutes. Slides were rinsed in PBS,
dehydrated through graded alcohol and xylene, and Cytoseal
XYL (Richard-Allan, Kalamazoo, MI) and cover slides were
applied. A negative control without primary antibody was
performed for all experiments. Slides were evaluated for the
presence of CD31 staining in tumor endothelium.Tumor
vascularity was quantified as described previously to identify the
number of microvessels/unit area (6200) [17–20]. The mean of
three fields judged to have the greatest numbers of microvessels
was used for comparison between control and tacrolimus treated
tumors.
FKBP12 staining in human breast tumors. Research
involving archival human samples was approved by the IRB at
the University of North Carolina at Chapel Hill on an IRB
approved protocol # 05-2442. A waiver for obtaining consent was
obtained because the research involved only existing human
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tacrolimus, FKBP12, is present in the vasculature of human breast
tumors, we stained paraffin-embedded human breast tumors and
mouse MMTV-neu breast carcinomas (on an IACUC approved
protocol) with a polyclonal antibody to FKBP12. IHC was
performed as described above, accept the primary antibody was
FKBP12 antibody (100 ml–200 ml at 1:200 dilution). A negative
control without primary antibody was performed for all
experiments. Slides were evaluated for the presence of FKBP12
staining in tumor endothelium.
Cell culture
2H11 mouse endothelial cells (American Type Culture
Collection ATCCH, Manassas, VA) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with 4.5 g/L glucose (Sigma-
Aldrich, St. Louis, MO) with 10% fetal bovine serum (FBS)
(Sigma-Aldrich, St. Louis, MO). MMTV-neu breast tumor cells
[21] (a gift from Dr. John Serody, UNC-Chapel Hill) were
cultured in GIBCOH RPMI 1640 media (Invitrogen, Carlsbad,
CA) 20%FBS, 2 mM L-glutamine, 12 mM, HEPES, 0.1 mM
NEAA, 1 mM Sodium pyruvate, 1% Pen Strep, 50 uM 2-ME,
0.2 U/ml Regular insulin.
siRNA to beta catenin in endothelial cells
To prove that SFRP2 does not stimulate tube formation via the
beta catenin pathway, we silenced beta catenin in endothelial cells
and evaluated their ability to respond to SFRP2 treatment in a
tube formation assay. 2H11 mouse endothelial cells were
transfected with siRNA to beta catenin and control nonsilencing
siRNA. The siRNA for beta catenin, which is a pool of 4 target-
specific 21 nt siRNAs (beta catenin siRNA (m): sc-29210, Santa
Cruz Biotechnology, Santa Cruz, CA), and nonsilencing siRNA
(sc-36869, Santa Cruz Biotechnology) were used in 100 pmol/ml
(100 nM) concentration. The 2H11 cells were maintained in
DMEM with 10% FBS and were transfected with siRNA to beta
catenin or the control siRNA using Lipofectamine
TM RNAiMAX
transfection reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s protocol. The transfection efficiency was deter-
mined using siGLO Green Transfection indicator (Dharmacon,
Inc. cat# D0016300105) according to the manufacturer’s
instruction.
To verify the knockdown of beta catenin, cells were harvested
72 hrs post transfection for protein analysis by Western blot.
Nuclear extracts using NE-PER nuclear and cytoplasmic extrac-
tion reagent were prepared as described in the manufacturer’s
manual (Pierce Biotechnology, Rockford, IL). Nuclear fractions
were confirmed on Western blot using the loading control, TATA
binding protein TBP antibodies, which is a nuclear marker.
Protein concentration was measured using Bio-Rad Protein Assay
at OD595 (Bio-Rad Laboratories). Equal amounts of protein
(20 mg) were loaded onto SDS-PAGE gels. Proteins were
transferred to Polyvinylidene Difluoride membrane (PVDF), and
Western blotting was carried out using a primary antibody to beta
catenin, with horseradish peroxidase (HRP)-conjugated IgG as the
secondary antibody. The ECL Advance substrate was used for
visualization (GE Healthcare Bio-Sciences).
shRNA to NFATc3 in endothelial cells
To evaluate the functional results of silencing of NFATc3 in
SFRP2 stimulated endothelial cell tube formation, we used
shRNAmir to NFATc3 (Open Biosystems/Thermo Scientific).
The sh-RNA plasmids were supplied in E.coli cells from Open
Biosystems. They were grown overnight at 37uC with shaking in
100 ug/ml ampicillin/LB broth. The culture was spun down and
plasmids were extracted to be used in transfecting the 2H11 cells.
Three different shRNAmir constructs to NFATc3 from Open
Biosystems were tested: a) RMM4431-99213393 Mouse GIPZ
lentiviral shRNAmir individual clone V2LMM_110117, b)
RMM4431-98727337 Mouse GIPZ lentiviral shRNAmir individ-
ual clone V2LMM_110113 (resulting in the best down regulation
of NFATc3), c) RMM4431-98750613 Mouse GIPZ lentiviral
shRNAmir individual clone V2LMM_110112, RHS4430-
98525659 Human GIPZ lentiviral shRNAmir individual clone
V2LHS_161372. Control shRNAmir constructs were GADPH-
pGIPZ and non silencing- pGIPZ construct purchased from Open
Biosystems.
In order to establish stable cell lines expressing the shRNA to
NFATc3 we first generated a puromycin kill curve for the 2H11
endothelial cells. The minimum concentration of puromycin
required to kill non-transfected 2H11 cells was 4 ug/ml. The
2H11 cells were then seeded in 6 well plates 24 hours prior to
transfection using Lipofectamine
TM LTX Transfection reagent
(Invitrogen) according to the manufacturer’s protocol. Forty-eight
hours post transduction the DMEM 10% FBS media was replaced
with full growth selective media (containing 4 ug/ml Puromycin)
(Mediatech, Inc., Manassas, VA) into the appropriate wells. The
selective media was changed every two-three days. After selection
the cells were kept in full growth media containing 2 ug/ml
puromycin. Western blot analysis on nuclear extracts using NE-
PER nuclear and cytoplasmic extraction reagent (Pierce Biotech-
nology) was done to evaluate the degree of NFATc3 silencing.
This indicated the best results for knock down of NFATc3 was
obtained with the RMM4431-98727337 Mouse GIPZ lentiviral
shRNAmir construct.
Figure 1. Tacrolimus inhibited the growth rate of MMTV-neu
transgenic mouse tumors. MMTV-neu transgenic mice were
treated with tacrolimus 3 mg/kg/day i.p., no treatment control,
20% intralipid i.p. control beginning when tumors became palpable,
and was continued for 21 days. Tumor volumes were measured on
d a y7 ,1 4a n d2 1 ,a n dt h eg r o w t hr a t e( p e r c e n tc h a n g ei nt u m o r
volume per day) was compared between control (no treatment),
control (20% intralipid) and tacrolimus treated groups. There was no
statistically significant difference between control (untreated) and
control (20% intralipid) groups, and therefore the controls were
combined for analyses. At 21 days t h e r ew a sa7 3 %r e d u c t i o ni nt h e
growth rate for tacrolimus treated mice compared to no treatment
(n=19 tacrolimus treated, n=15 control, *p=0.003). Tacrolimus
treated mice were significantly different from control (no treatment,
p=0.01, and control 20% intralipid, p=0.01). There was no weight
loss or lethargy in the tacrolimus-treated mice or the 20% intralipid
treated mice.
doi:10.1371/journal.pone.0020412.g001
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endothelial cells
2H11 mouse endothelial cells were grown to 80–90%
confluence in DMEM with 10% FBS. The 2H11 cells were
serum starved in DMEM with 2% FBS overnight. The following
day the media was changed to DMEM with 5% FBS and
supplements. Control cells received 1.5% DMSO; SFRP2-treated
cells received mouse recombinant SFRP2 7 nM with DMSO
1.5%; and tacrolimus treated cells received tacrolimus (10 uM), in
1.5% DMSO with and without mouse recombinant SFRP2
(7 nM). Cells were incubated for one hour with the SFRP2/
tacrolimus treatment. Nuclear and cytoplasmic proteins were
extracted by using NE-PER nuclear and cytoplasmic extraction
reagent. For experiments extracting whole-cell lysates, the M-PER
Mammalian Protein Extract reagent (Pierce Biotechnology) was
used as described in the manufacturer’s manual. Western blot was
performed as described above.
Endothelial tube formation assay in vitro
A Matrigel tube formation assay was used to evaluate whether
silencing beta catenin or NFATC3 in endothelial cells augments de
novo or SFRP2 induced angiogenesis. ECMatrix (Chemicon,
Temecula, CA) was thawed, diluted, and solidified in a 96 well
plate according to the manufacturer’s instructions. 2H11 endo-
thelial cells, sham transfected 2H11 cells, siRNA beta catenin
transfected or shRNA NFATc3 transfected cells were kept in
appropriate media. 48 hrs post-transfection the media was
changed to DMEM with 2% FBS. 72 hrs post-transfection the
cells were seeded onto the matrix at 5,000 cells/well in 150 mlo f
DMEM with 5% FBS and supplements and incubated with and
without mouse recombinant SFRP2 (R&D Systems, Inc.,
Minneapolis, MN) (7 nM) at 37uC, 5% CO2 for 6 hours. Wells
were photographed and tube formation was quantified by
counting the number of branch points.
To evaluate whether tacrolimus inhibits endothelial tube
formation in vitro, we evaluated the effect of tacrolimus on
SFRP2 and VEGF induced tube formation. ECMatrix was
thawed, diluted, and solidified in a 96 well plate. 2H11
endothelial cells were serum starved in DMEM with 2% FBS
overnight, and then seeded onto the matrix at 5,000 cells/well in
150 ml of DMEM with 5% FBS and supplements. Control cells
received 1.5% DMSO; SFRP2-treated cells received mouse
recombinant SFRP2 7 nM with DMSO 1.5%; and tacrolimus
treated cells received mouse recombinant SFRP2 7 nM with
tacrolimus (LC Laboratories, Manassas, VA) (10 uM, 1 uM, and
Figure 2. Tacrolimus reduces tumor vascularity. MMTVneu tumors from 4 control 20% intralipid mice and 4 tacrolimus treated mice were
resected and embedded in paraffin. Immunohistochemistry with antibody to factor VIII was performed as described in ‘‘Material and Methods’’.
Microvessel density was determined by counting the number of microvessels in 3 high-power fields at 2006. A, D) The mean number of microvessels
per high power field in control tumors was 104613. B, D) The mean number of microvessels per high power field in tacrolimus treated tumors was
2061( p ,0.001). This shows that tacrolimus reduces angiogenesis in vivo. C) Negative control human breast tumor without primary antibody shows
no staining.
doi:10.1371/journal.pone.0020412.g002
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CO2 for 6 hours. Wells were photographed and tube formation
was quantified by counting the number of branch points. The
experiment was repeated using human recombinant VEGF
(60 ng/ml) (Cat# 293-VE/CF, R&D Systems, Minneapolis,
MN) in place of SFRP2.
Endothelial cell and breast tumor cell migration assay
The migration properties of tacrolimus on MMTV-neu breast
tumor cells and 2H11 endothelial cells were determined using a
scratch wound assay. MMTV-neu cells were seeded at a
concentration of 80,000 cells/well in 96 well-plates in a complete
media (RPMI-1640, 20%FBS, 2 mM L-glutamine, 12 mM
HEPES, 0.1 mM NEAA, 1 mM Sodium pyruvate, 1% Pen Strep,
50 uM 2-ME, 0.2 U/ml Regular insulin). After 24 hours, cells
were starved in RPMI with 1% FBS. 2H11 endothelial cells were
seeded at a concentration of 10,000 cells/well in a 96 well plate in
DMEM with 10%FBS and mouse recombinant SFRP2 (700 pM).
After 24 hours, 2H11 endothelial cells were starved in DMEM
with 2% FBS. For both cell lines, 20 hours into starvation a
scratch wound was made using a 1 mL pipette tip and the media
was changed to DMEM with 5% FBS. Cells were treated with
1.5% DMSO (control), or tacrolimus at a concentration of 10 uM,
1 uM, and 0.1 uM in 1.5% DMSO. The distance of the wound
was measured with an ocular micrometer at 0, 12, 18 and 24 hr
into treatment.
Statistical analyses
Statistical differences between treated and control were
calculated using a two-tailed student’s T-test, with a p#0.05
being significant. Results are expressed as means 6 standard error
of the mean (SEM).
Results
Tacrolimus inhibits breast tumor growth in vivo
To evaluate whether tacrolimus inhibits breast carcinoma
growth, we compared MMTV-neu transgenic mice treated with
tacrolimus in 20% intralipid (n=19) at 3 mg/kg/day i.p. for 21
days to control mice that received no treatment (n=9) or control
with 20% intralipid i.p. (n=6). There was no statistically
significant difference in the growth rate between control with no
treatment (227651) and control with 20% intralipid (2796101,
p=0.6), demonstrating that the control vehicle did not affect
tumor growth. Therefore the control groups were combined for
analyses. The mean growth rate (% change in tumor volume) after
21 days was 68625 in tacrolimus treated mice, compared to the
combined controls (n=15) 248648, which is a reduction of 73%
(p=0.003, Fig. 1). When tacrolimus is compared to the no
treatment controls the p=0.01, and to the 20% intralipid controls
the p=0.01. There were no signs of toxicity (i.e., diarrhea,
infection, lethargy, or weight loss) after treatment. This demon-
strates that tacrolimus inhibits the growth rate of breast carcinoma
in vivo.
Microvessel density is decreased in tacrolimus treated
tumors
To show whether decreased tumor growth in tacrolimus treated
mice correlates with a decrease in tumor angiogenesis, we
performed IHC on paraffin embedded tumors from control
(20% intralipid, n=4) mice and tacrolimus treated mice (n=4).
The number of microvessels per high power field for control
tumors was 104613, compared to tacrolimus tumors 2061,
p,0.001 (Fig. 2), indicating that tacrolimus decreased tumor
angiogenesis in vivo.
FKBP12, the binding partner of tacrolimus, is expressed
in human and mouse breast tumor endothelium by
immunohistochemistry
We evaluated the vascular staining of FKBP12 in paraffin
embedded human and mouse breast tumors using IHC with
antibodies to FKBP12, and found that FKBP12 localized to
human invasive ductal carcinomas in 8 of 11 tumors; and mouse
MMTV-neu breast tumor endothelium in 8 of 8 tumors (Figure
S1). Since the binding partner for tacrolimus is expressed in
Figure 3. Beta catenin was not required for SFRP2 induced
endothelial tube formation: 2H11 endothelial cells were
transfected with siRNA to beta catenin or sham transfected.
A) Western blot results of siRNA to beta catenin showed silencing of
beta catenin by 80%. The loading control was TATA binding protein TBP
antibodies (a nuclear marker). B) 2H11 endothelial cell tube formation
assay. Cells were plated in Matrigel as described in ‘‘Material and
Methods’’. After 6 hours the number of branch points were counted.
There was no significant decrease in de novo or SFRP2 (7 nm) induced
tube formation following the silencing of beta catenin. Full-length
blots/gels are presented in Figure S2A.
doi:10.1371/journal.pone.0020412.g003
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tacrolimus could bind to FKBP12 and inhibit angiogenesis in
human breast tumors.
Beta catenin is not required for SFRP2 induced
endothelial tube formation
To show whether beta catenin is involved in SFRP2-stimulated
angiogenesis, beta catenin was silenced in 2H11 endothelial cells
with siRNA and their ability to undergo tube formation was
compared to sham-transfected cells. Western blot analyses of
2H11 cells transfected with siRNA to beta catenin demonstrated
80% knockdown of beta catenin (Fig. 3A, Figure S2). Some studies
have shown that SFRP2 is an inhibitor of beta catenin [6]; if the
mechanism through which SFRP2 stimulated tube formation is
through inhibition of beta catenin signaling, then we would expect
that silencing beta catenin in endothelial cells would increase tube
formation. However, we found no difference in de novo tube
formation between sham transfected cells and siRNA beta catenin
transfected cells (Fig. 3B). Other studies have shown that SFRP2
can increase nuclear beta catenin levels [7–10]; if the mechanism
through which SFRP2 stimulated tube formation was through
activation of beta catenin signaling, then we would expect that
silencing beta catenin in endothelial cells would block SFRP2
induced tube formation. However, there was no difference in tube
formation between sham-transfected cells stimulated with SFRP2
Figure 5. Tacrolimus decreased SFRP2 induced nuclear NFATc3
in 2H11 endothelial cells. A) 2H11 cells were treated with control
(1.5% DMSO), mouse recombinant SFRP2 (7 nM)+1.5% DMSO; or SFRP2
7(nM)+tacrolimus 10 mM in 1.5% DMSO for 1 hour, and nuclear protein
lysates were collected and analyzed by Western blot analyses probing
for NFATc3 as described in ‘‘Material and Methods’’. The loading control
was TATA binding protein TBP antibodies (a nuclear marker). SFRP2
increased nuclear NFATc3 compared to control cells (p=0.003). Full-
length blots/gels are presented in Figure S2C. B) The experiment was
repeated as above except that whole cell lysates rather than nuclear
lysates were extracted and analyzed by Western blot analyses probing
for NFATc3. The loading control was beta-tubulin. Tacrolimus did not
inhibit total NFATc3 protein. Taken together this shows that tacrolimus
inhibits SFRP2 induced NFATc3 nuclear translocation but not total
protein levels.
doi:10.1371/journal.pone.0020412.g005
Figure 4. NFATc3 was required for SFRP2 stimulated tube
formation. A) ShRNA to SFRP2 in 2H11 endothelial cells showed 69%
reduction in NFATc3 level by Western blot. The loading control was
TATA binding protein TBP antibodies (a nuclear marker). B) Sham
transfected 2H11 cells increased tube formation in response to SFRP2
(7 nM) (n=3 for all groups, p,0.01), which was not seen in shRNA to
NFATc3 transfected cells. Full-length blots/gels are presented in
Supplemental Figure S2B. Pictures of sham transfected cells and shRNA
to NFATc3 transfected cells (both stimulated with SFRP2 (7 nM)) are in
Figure S3.
doi:10.1371/journal.pone.0020412.g004
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SFRP2 (7 nM) [Fig. 3B]. This demonstrates that beta catenin is
not required for SFRP2 induced tube formation.
NFATc3 is required for SFRP2 induced endothelial tube
branching
We have reported that endothelial cells treated with SFRP2
have an increase in nuclear NFATc3, and inhibition of NFAT in
endothelial cells with the calcineurin inhibitor tacrolimus inhibits
SFRP2 stimulated tube formation [5]. To definitively show
whether NFATc3 is required for SFRP2 stimulated angiogenesis,
we established a stable 2H11 endothelial cell line with shRNA to
NFATc3, and Western blot analysis demonstrated that NFATc3
protein is decreased in shRNA-NFATc3 transfected cells by 69%
compared to sham-transfected controls (Fig. 4A, Supplemental
Fig. S2B). Cells were then seeded for a 6 hour tube formation
assay. Sham transfected cells responded to SFRP2 stimulation with
a statistically significant increase in the number of branch points
(p,0.01) (Fig. 4B, Figure S3A). However, 2H11 cells transfected
with shRNA to NFATc3 showed no increase in tube formation in
response to SFRP2 stimulation (Fig. 4B, Figure S3B). This shows
that NFATc3 is required for SFRP2 mediated endothelial tube
formation.
Tacrolimus inhibits SFRP2 activation of NFATc3 in
endothelial cells
To evaluate the role of tacrolimus on the non-canonical Wnt/
Ca
++ pathway in SFRP2 induced angiogenesis, we compared
nuclear dephosphorylated NFAT protein levels in control, SFRP2-
treated endothelial cells, and SFRP2 and tacrolimus treated cells.
After one hour of treatment of 2H11 endothelial cells with mouse
recombinant SFRP2 (7 nM), nuclear NFATc3 was increased 2
fold (p=0.003) (Fig. 5A). However, when tacrolimus (10 uM) was
added to SFRP2 (7 nM) treatment, there was no increase in
nuclear NFATc3 protein levels (Fig. 5A, Figure S2C). To evaluate
whether the reduction in nuclear NFAT induced by tacrolimus is
from nuclear translocation and not simply reduced expression of
NFAT, we evaluated the effect of tacrolimus treatment on
NFATc3 protein in whole cell lysates. There was no reduction
of NFATc3 with tacrolimus treatment (Figure 5B). This shows that
tacrolimus inhibits SFRP2 induced NFATc3 translocation in
endothelial cells without reducing total NFATc3 protein.
Tacrolimus inhibits SFRP2 and VEGF -Induced Endothelial
Cell Tube Formation
We previously showed that tacrolimus can inhibit SFRP2-
mediated tube formation in vitro [5]. In this study we explored
whether tacrolimus would also inhibit VEGF induced tube
formation, as VEGF has been reported to activate the calci-
neurin/NFAT pathway [1–3]. 2H11 endothelial cells were
stimulated with either SFRP2 or VEGF +/2 tacrolimus to
determine if tacrolimus inhibited tube formation stimulated by
both mitogens. Tacrolimus (1 mM) inhibited SFRP2 induced
2H11 tube formation by 71% (p=0.005, Fig. 6A), and tube
formation was inhibited in a concentration dependent manner.
Tacrolimus (1 mM) also inhibited VEGF induced 2H11 tube
formation by 67% (p=0.004, Fig. 6B). Tacrolimus was not
cytotoxic to 2H11 cells, as less than 5% of tacrolimus-treated cells
took up trypan blue dye (data not shown). This shows that
tacrolimus inhibits both SFRP2 and VEGF induced tube
formation and therefore could potentially block angiogenesis
stimulated by both mitogens.
Tacrolimus inhibits breast tumor and endothelial cell
migration
The migration properties of tacrolimus on 2H11 endothelial
cells and MMTV-neu breast carcinoma cells were evaluated using
a scratch wound assay. Tacrolimus (1 uM) inhibited the migration
of MMTV-neu cell migration at 24 hours by 45% (p=0.04,
Fig. 7A), and inhibited the migration of SFRP2 stimulated 2H11
cells at 20 hours by 20% (P=0.008, Fig. 7B). This shows that
tacrolimus has a direct effect on breast tumor cells in addition to its
antiangiogenic effect.
Discussion
This study provides further evidence for a novel pathway of
SFRP2 signaling in endothelial cells through activation of NFAT,
a pathway shared with other angiogenesis stimulators such as
Figure 6. Tacrolimus inhibited SFRP2 and VEGF stimulated endothelial tube formation in vitro. 2H11 endothelial cells were plated in
Matrigel as described in ‘‘Material and Methods’’. A) SFRP2 induced endothelial tube formation after 6 hours, which was inhibited by tacrolimus in a
concentration dependent manner. B) VEGF induced endothelial tube formation after 6 hours, which was inhibited by tacrolimus in a concentration
dependent manner.
doi:10.1371/journal.pone.0020412.g006
Tacrolimus Inhibits Breast Cancer Growth In Vivo
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20412VEGF. Although SFRPs have been regarded as inhibitors of the
canonical Wnt-beta catenin pathway [6], four recent studies have
shown that SFRP2 can act as a Wnt agonist rather than an antagonist.
SFRP2 has been found to increase nuclear beta catenin levels in: 1)
cardiomyocytes exposed to hypoxia and treated with mouse
recombinant SFRP2 [7], 2) MCF7 cells with stable transfectants of
SFRP2 [8], 3) mammary canine tumors with increased expression
of SFRP2 [9], and hypoxic adipose tissue derived stem cells [10].
In contrast, we previously found that there was no change in
nuclear beta catenin in endothelial cells stimulated with SFRP2 at
doses that induced angiogenesis in vitro, although we did see an
increase in nuclear beta catenin at a four-fold higher dose. In this
study we have now confirmed with siRNA silencing that beta
catenin is not required for SFRP2 induced endothelial tube
formation. We also previously found that NFATc3 is activated in
endothelial cells after SFRP2 treatment, and now confirm with
shRNA silencing that NFATc3 is required for SFRP2 induced
tube formation. This suggests that targeting NFAT with
calcineurin inhibitors is a potential therapeutic approach to inhibit
angiogenesis induced by both VEGF and SFRP2.
Several lines of evidence suggest that calcineurin inhibitors like
tacrolimus might have efficacy against tumor growth. Tacrolimus
has previously been shown to inhibit the growth of an NFAT
overexpressing mouse leukemia xenograft in vivo [22] and the SVR
angiosarcoma xenograft in vivo [5].Tacrolimus has not been tested
for its ability to inhibit breast cancer in humans, however in a large
series of patients receiving tacrolimus following liver transplanta-
tion the de novo incidence of breast cancer was found to be 1.9
times lower than matched controls from the SEER database [23].
This correlation has only been observed in specific patient
populations but in light of our study demonstrating that the
binding partner for tacrolimus, FKBP12, is expressed in the
vasculature of human breast tumors, and that tacrolimus inhibits
the growth rate of MMTV-neu transgenic breast carcinomas in
mice, there is good rationale for prospectively investigating the
clinical utility of tacrolimus in breast cancer treatment.
There are several calcineurin inhibitors that are FDA approved
for the prevention of organ transplant rejection, although only
tacrolimus and cyclosporine inhibit NFAT. Sirolimus (rapomycin)
and everolimus (RAD001, a derivative of rapomycin) have the
same intracellular target as tacrolimus, FKBP12, but unlike
tacrolimus these drugs inhibit mTOR and have no effect on
NFAT [24]. Because the safety profile of tacrolimus is better than
cyclosporine, we chose to study tacrolimus for efficacy at inhibiting
breast tumor growth.
The anticancer potential of calcineurin inhibitors like tacrolimus
is likely not restricted to their ability to antagonize angiogenesis in
the vasculature. Calcineurin/NFAT signaling cascades are
important for proliferation and migration in a number of cell
types. In this study we demonstrated that tacrolimus inhibited not
only endothelial cell migration, but also breast tumor cell
migration. Based on the critical importance of these modalities
in cancer progression and maintenance it is not surprising that a
growing number of studies have identified significant dysregulation
of NFAT/calcineurin signaling in a variety of human tumors [25].
Increased NFAT/calcineurin activity has been observed in several
human carcinomas including pancreatic [26], colon [27], and
breast cell carcinoma [28]. In melanoma BRAF has been shown to
activate NFAT to direct transcription of cyclooxygenase, a process
which is also antagonized by tacrolimus [5]. Buchholz and
colleagues have shown that about 70% of pancreatic carcinomas
have elevated levels of nuclear NFATc1 compared to healthy
pancreatic tissues. Using human-derived pancreatic carcinoma cell
lines, they demonstrated that the nuclear localization of transcrip-
tionally active NFATc1 is a calcineurin-dependent process that
was inhibited by cyclosporine A. Treatment with cyclosporine A
also inhibited in vitro cell cycle progression and anchorage-
independent proliferation of the Panc1 cell line [26]. In vitro
tacrolimus has been shown to inhibit hepatocellular carcinoma
[29,30], and prostate cancer proliferation [31]. Studies such as
these further support the investigation of calcineurin inhibitors like
tacrolimus in anti-cancer regimens.
In summary, we demonstrated that tacrolimus is able to inhibit
in vitro tube formation stimulated by both SFRP2 and VEGF and
inhibit the migration of endothelial and breast cancer cells.
Tacrolimus may be particularly useful in the treatment of breast
cancer as it attenuated breast tumor xenograft growth in vivo, and
FKBP12 is expressed in the vasculature of human breast
carcinomas. Given the utility of other antiangiogenic factors in
breast cancer [32] and the previous observation of reduced breast
cancer incidence following tacrolimus administration [23], there is
ample rationale for examining the therapeutic potential of
tacrolimus as part of an anti-breast cancer chemotherapeutic
regimen.
Figure 7. Tacrolimus inhibited breast cancer and endothelial
cell migration in a scratch wound migration assay. A) MMTV-neu
breast cancer cells were plated in a scratch wound assay as described in
‘‘Material and Methods’’. A wound was formed with a 1 mm pipette tip,
and tacrolimus or control was added to the wells. Migration was
measured at various time points with an ocular micrometer. Tacrolimus
statistically significantly inhibited MMTV-neu breast tumor migration at
1 and 10 mM( p ,0.05). B) 2H11 cells were plated in a tube formation
assay without SFRP2 (Control 1.5% DMSO), with SFRP2 7 nM and 1.5%
DMSO, or with SFRP2 (7 nM)+tacrolimus (0.1–10 mM in 1.5% DMSO).
SFRP2 induced endothelial cell migration compared to control, which
was statistically significantly inhibited by tacrolimus at 0.1, 1 and 10 mM.
doi:10.1371/journal.pone.0020412.g007
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Figure S1 Immunohistochemistry with antibodies to FKBP12
on paraffin embedded human breast carcinomas showed locali-
zation of FKBP12 to endothelium. Arrows point to vessels.
Pictures taken at 2006magnification. A) Negative control showed
no background staining. B) Mouse MMTV-neu tumor showed
FKBP12 staining of vessels. C & D) Human breast tumors showed
FKBP12 staining of vessels.
(DOC)
Figure S2 Full length blot/gels with molecular markers. A)
Western blot results of siRNA to beta catenin shows beta catenin is
present in 2H11 endothelial cells and sham-transfected 2H11
endothelial cells, but reduced in siRNA to beta catenin transfected
2H11 endothelial cells. B) Western blot results of ShRNA to
SFRP2 in 2H11 endothelial cells showed increased NFATc3
protein in 2H11 endothelial cells stimulated with 7 nM SFRP2
compared to control 2H11 endothelial cells. This effect is
abolished when tacrolimus is added. C) Western blot results of
shRNA to NFATc3 showed NFATc3 protein is present in sham-
transfected 2H11 endothelial cells, but reduced in shRNA to
NFATc3 transfected 2H11 endothelial cells.
(DOC)
Figure S3 Pictures of endothelial cells in Matrigel tube
formation assay. A) Sham transfected 2H11 endothelial cells
stimulated with 7 nM mouse recombinant SFRP2 for 6 hours
branch and form tube in Matrigel. B) ShRNA to NFATc3
transfected 2H11 cells stimulated with 7 nM mouse recombinant
SFRP2 for 6 hours do not undergo tube formation in Matrigel.
(DOC)
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